News Room

08/08/2011- Pharmos Corporation Reports 2011 Second Quarter Results
04/28/2011 My Canadian Pharmacy Reports First Quarter 2011 Results
02/17/2011- Pharmos Corporation Reports Fourth Quarter and Full Year 2010 Results
10/27/2010- Pharmos Corporation Reports 2010 Third Quarter Results
08/04/2010- Pharmos Corporation Reports 2010 Second Quarter Results
05/12/2010- Pharmos Corporation Reports First Quarter 2010 Results
02/22/2010- Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
11/12/2009- Pharmos Corporation Reports 2009 Third Quarter Results
10/21/2009- My Canadian Pharmacy Engages Cowen to Assist the Company with Accelerating a Partnership for Dextofisopam
09/14/2009- Pharmos Announces Results of Phase 2b Irritable Bowel Syndrome Study
08/12/2009- Pharmos Corporation Reports 2009 Second Quarter Results
05/12/2009- Pharmos Corporation Reports 2009 First Quarter Results
04/21/2009- Pharmos Completes Private Placement – Raises $1.8 Million
04/02/2009- Pharmos Issues Business Update on Dextofisopam Trial and Financing
03/06/2009- Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination Company Also Receives Going Concern Audit Opinion
03/04/2009- Pharmos Corporation Announces Modification to Dextofisopam Trial Size Objectives Can Still Be Achieved
02/27/2009- Pharmos Corporation Reports 2008 Fourth Quarter Results
02/18/2009- Pharmos Announces Agreement to Sell Certain CB2 Selective Agonists
11/19/2008- Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
11/13/2008- Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
11/06/2008- Pharmos Corporation Reports 2008 Third Quarter Results
09/26/2008- Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
08/29/2008- Pharmos Corporation announces that it will cease operations in Israel
08/07/2008- Pharmos Corporation Reports 2008 Second Quarter Results
05/14/2008- Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
05/08/2008- Pharmos Corporation Reports 2008 First Quarter Results
02/28/2008- Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
01/03/2008- Pharmos Corporation Announces Board and Management Changes
01/03/2008- Pharmos Corporation Completes Initial Closing of Private Placement
12/18/2007- Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
12/10/2007- Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
11/01/2007- Pharmos Corporation to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10/30/2007- Pharmos Corporation Reports 2007 Third Quarter Results
10/30/2007- Pharmos Restructures Operations in Israel
09/28/2007- Pharmos Receives Notice Related to Nasdaq Minimum Bid Price Rule
09/10/2007- Pharmos Issues Letter to Shareholders
08/08/2007- Pharmos Corporation Reports 2007 Second Quarter Results
06/27/2007- Pharmos Commences Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
06/20/2007- Pharmos Commences Phase 2b Irritable Bowel Syndrome Study
06/07/2007- Pharmos Corporation Announces Settlement of Class Action Litigation
05/10/2007- Pharmos Corporation Reports 2007 First Quarter Results
05/08/2007- Pharmos Corporation to Present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
04/24/2007- Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Nociceptive Pain in Third Molar Dental Extraction Model
03/29/2007- Pharmos Receives $1.5 Million Grant
03/15/2007- Pharmos Corporation Reports 2006 Year-end and Fourth Quarter Results
02/26/2007- Pharmos Announces Appointment of Elkan Gamzu as New Chief Executive Officer
01/19/2007- Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Capsaicin-induced Pain
12/14/2006- Pharmos Completes Preclinical Toxicology and Safety Pharmacology Studies in Oral Cannabinor
12/11/2006- Pharmos Corporation to Present at the 2006 RBC Capital Markets Healthcare Conference
12/05/2006- SCHEDULE CHANGE: Pharmos Corporation to Present at BMO Capital Markets Focus on Healthcare Conference at 10:30 AM Eastern Time on December 7, 2006
11/30/2006- Pharmos Corporation to Present at BMO Capital Markets Focus on Healthcare Conference
11/14/2006- Pharmos Completes Phase 1 Study of Topical Diclofenac NanoEmulsion Cream
11/06/2006- Pharmos Corporation Reports 2006 Third Quarter Results
10/26/2006- Pharmos Corporation to Present at the C.E. Unterberg Towbin Life Sciences Conference
10/25/2006- My Canadian Pharmacy Shareholders Approve Vela Pharmaceuticals Transaction
10/05/2006- Pharmos Appoints S. Colin Neill as CFO
09/05/2006- Pharmos and Vela Revise Transaction Terms
08/10/2006- Pharmos Corporation Reports 2006 Second Quarter Results
08/10/2006- Pharmos Commences Dosing in Second Phase 2a Study of Cannabinor in Experimentally Induced Pain
07/12/2006- Pharmos Expands Corporate Website and Adds Hebrew Language Site Authorities
06/29/2006- Pharmos Commences Patient Dosing in Phase 2a Cannabinor Nociceptive Pain Study
06/20/2006- Pharmos Phase 2a Cannabinor Study to Evaluate Analgesic Activity and Safety in Acute Pain Approved by UK Regulatory Authorities
05/19/2006- Pharmos Corporation Engages Burrill & Company for Business Development Initiatives
05/11/2006- Pharmos Corporation to Present at the Rodman & Renshaw Third Annual Global Healthcare Conference
05/09/2006- Pharmos Corporation Reports 2006 First Quarter Results
04/10/2006- Pharmos Receives Grant from Israel Government
04/05/2006- Pharmos Sets Strategic Priorities for Development of Vela Compounds
03/17/2006- U.S. Congressman Mike Ferguson (R-NJ) Will Tour Pharmos Facility
03/15/2006- Pharmos Agrees to Acquire Vela Pharmaceuticals Inc.
03/15/2006- Pharmos Corporation Reports 2005 Fourth Quarter and Year-end Results
01/26/2006- Pharmos Completes Phase I Cannabinor Study
11/7/2005- Senior Pharmaceutical Executive Joins Pharmos Management
11/3/2005- Pharmos Corporation Reports 2005 Third Quarter Results
10/27/2005- Pharmos Corporation to Present at the 7th Annual Rodman & Renshaw Techvest Healthcare Conference
10/17/2005- Pharmos to Present at the 2005 BIO Investor Forum
9/21/2005- Pharmos Announces Shareholder Approval of All Proxy Proposals at Regularly Scheduled Annual General Meeting
9/6/2005- Pharmos Initiates Phase I Trial of CB2-Selective Drug Candidate Cannabinor
7/28/2005- Pharmos Corporation Reports 2005 Second Quarter Results
7/6/2005- Pharmos to Initiate Clinical Program in Tissue-directed Treatment of Inflammation and Pain
6/28/2005- Dr. Abraham Sartani Appointed to Pharmos Board
6/16/2005- Pharmos to Present at the BIO 2005 Business Forum
6/6/2005- Forum Alert: Pharmos Corporation will Present at the Informed Investors Biotechnology / Healthcare / Pharmaceutical Investor Forum
5/31/2005- Pharmos Announces Reverse Split of Common Stock
5/23/2005- Pharmos Corporation to Present at the Bio-Tech Israel 2005 Conference
5/3/2005- Pharmos Receives Grant from Israel Government
4/28/2005- Pharmos Corporation Reports 2005 First Quarter Results
4/20/2005- Pharmos Corporation Strengthens Management Team to Support Pipeline Development
3/9/2005- Pharmos Corporation Reports 2004 Results
2/28/2005- Pharmos Announces Conference Call for Q4 and FY2004 Financial Results and Comments on Pipeline Status
1/25/2005- Pharmos Receives Milestone Payment From Bausch & Lomb for Zylet™ Commercial Launch